LSE - Small Logo
LSE - Small Logo

Valentina Lichtner

May 6th, 2015

Battles for market control in the field of generics – news from The Economist

0 comments

Estimated reading time: 5 minutes

Valentina Lichtner

May 6th, 2015

Battles for market control in the field of generics – news from The Economist

0 comments

Estimated reading time: 5 minutes

“This week Mylan, based in the Netherlands, rejected a $40 billion bid from Teva, of Israel, arguing that it “lacks industrial logic”. To be on the safe side it has enacted a poison-pill defence against hostile takeover. Combining the world’s largest generic-drug maker, Teva, with the third-largest, Mylan, would create a company with around $30 billion in annual revenues and, Teva says, $2 billion in cost savings. As part of its plan to escape Teva’s clutches, Mylan has made three successive takeover offers to Perrigo, a smaller Irish rival, only to be spurned each time. Perrigo now seems likely to attract interest from other companies.”

The Economist, May 2nd 2015,
Generic drugs: Much ado about something
http://www.economist.com/news/business/21650151-worries-are-growing-about-effects-dealmaking-among-generics-firms-much-ado-about

About the author

Valentina Lichtner

Posted In: Business | Medicines | Value

Leave a Reply

Your email address will not be published. Required fields are marked *

Meta